Saccharomyces boulardii Administration Changes Gut Microbiota and Attenuates D-Galactosamine-Induced Liver Injury

[1]  Lanjuan Li,et al.  Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology , 2016, Scientific Reports.

[2]  Lanjuan Li,et al.  Deep sequencing reveals microbiota dysbiosis of tongue coat in patients with liver carcinoma , 2016, Scientific Reports.

[3]  F. Lu,et al.  Effects of different diets on intestinal microbiota and nonalcoholic fatty liver disease development. , 2016, World journal of gastroenterology.

[4]  Guoyao Wu,et al.  Interferon Tau Affects Mouse Intestinal Microbiota and Expression of IL-17 , 2016, Mediators of inflammation.

[5]  F. Servant,et al.  Triggering the adaptive immune system with commensal gut bacteria protects against insulin resistance and dysglycemia , 2016, Molecular metabolism.

[6]  L. Vitetta,et al.  Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease , 2016, Therapeutic advances in gastroenterology.

[7]  C. Kao,et al.  Risk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patients , 2016, Scientific Reports.

[8]  A. Marino Gammazza,et al.  Alcoholic Liver Disease: A Mouse Model Reveals Protection by Lactobacillus fermentum , 2016, Clinical and Translational Gastroenterology.

[9]  Weiyun Zhu,et al.  Characterising the bacterial microbiota across the gastrointestinal tracts of dairy cattle: membership and potential function , 2015, Scientific Reports.

[10]  H. Szajewska,et al.  Systematic review with meta‐analysis: Saccharomyces boulardii in the prevention of antibiotic‐associated diarrhoea , 2015, Alimentary pharmacology & therapeutics.

[11]  James Kinross,et al.  The gut microbiota and host health: a new clinical frontier , 2015, Gut.

[12]  B. Schnabl,et al.  The Gut Microbiota and Liver Disease , 2015, Cellular and molecular gastroenterology and hepatology.

[13]  W. Bernal,et al.  Update on acute liver failure , 2015, Current opinion in critical care.

[14]  M. Minemura,et al.  Gut microbiota and liver diseases. , 2015, World journal of gastroenterology.

[15]  Feixiong Cheng,et al.  FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach , 2015, Scientific Reports.

[16]  Ming Li,et al.  Oral Administration of Saccharomyces boulardii Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis in Rats via Reducing Intestinal Permeability and Modulating Gut Microbial Composition , 2015, Inflammation.

[17]  Ming Li,et al.  Oral Administration of Saccharomyces boulardii Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis in Rats via Reducing Intestinal Permeability and Modulating Gut Microbial Composition , 2014, Inflammation.

[18]  D. Teng,et al.  Saccharomyces boulardii prevention of the hepatic injury induced by Salmonella Enteritidis infection. , 2014, Canadian journal of microbiology.

[19]  Beiwen Zheng,et al.  Alterations of the human gut microbiome in liver cirrhosis , 2014, Nature.

[20]  Patrice D Cani,et al.  Saccharomyces boulardii Administration Changes Gut Microbiota and Reduces Hepatic Steatosis, Low-Grade Inflammation, and Fat Mass in Obese and Type 2 Diabetic db/db Mice , 2014, mBio.

[21]  R. Aggarwal,et al.  Gut microbiota and liver disease , 2014, Journal of gastroenterology and hepatology.

[22]  A. Czaja,et al.  Hepatic inflammation and progressive liver fibrosis in chronic liver disease. , 2014, World journal of gastroenterology.

[23]  Thierry F. Vandamme,et al.  Use of rodents as models of human diseases , 2014, Journal of pharmacy & bioallied sciences.

[24]  L. Duan,et al.  Bacterial Community Mapping of the Mouse Gastrointestinal Tract , 2013, PloS one.

[25]  M. Luyer,et al.  The gut-liver axis , 2013, Current opinion in clinical nutrition and metabolic care.

[26]  J. Qi,et al.  Metagenomic sequencing reveals microbiota and its functional potential associated with periodontal disease , 2013, Scientific Reports.

[27]  E. Comelli,et al.  Intestinal microbiota in patients with nonalcoholic fatty liver disease , 2013, Hepatology.

[28]  Laure-Alix Clerbaux,et al.  Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways. , 2013, Molecular nutrition & food research.

[29]  S. Rabot,et al.  Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice , 2012, Gut.

[30]  William A. Walters,et al.  Using QIIME to Analyze 16S rRNA Gene Sequences from Microbial Communities , 2012, Current protocols in microbiology.

[31]  I. Castro,et al.  Adhesion to the yeast cell surface as a mechanism for trapping pathogenic bacteria by Saccharomyces probiotics. , 2012, Journal of medical microbiology.

[32]  K. Reddy,et al.  Bacterial infections in end-stage liver disease: current challenges and future directions , 2012, Gut.

[33]  G. Nardone,et al.  Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. , 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[34]  M. Mori,et al.  Cytokines and STATs in Liver Fibrosis , 2012, Front. Physio..

[35]  Rob Knight,et al.  Using QIIME to Analyze 16S rRNA Gene Sequences from Microbial Communities , 2011, Current protocols in bioinformatics.

[36]  R. Meli,et al.  Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. , 2011, The Journal of nutritional biochemistry.

[37]  Rob Knight,et al.  UCHIME improves sensitivity and speed of chimera detection , 2011, Bioinform..

[38]  L. Mcfarland.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. , 2010, World journal of gastroenterology.

[39]  P. Bork,et al.  A human gut microbial gene catalogue established by metagenomic sequencing , 2010, Nature.

[40]  A. Dolganiuc,et al.  VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet‐induced nonalcoholic steatohepatitis model in mice , 2009, Hepatology.

[41]  N. Shanks,et al.  Are animal models predictive for humans? , 2009, Philosophy, ethics, and humanities in medicine : PEHM.

[42]  H. Lee.  Acute liver failure related to hepatitis B virus , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[43]  G. Garcia‐Tsao,et al.  Probiotics and Liver Disease , 2008, Journal of clinical gastroenterology.

[44]  M. Devonald,et al.  Current opinion in clinical nutrition and metabolic care. , 2008, Current opinion in clinical nutrition and metabolic care.

[45]  S. Ahrné,et al.  Endotoxin- and D-galactosamine-induced liver injury improved by the administration of Lactobacillus, Bifidobacterium and blueberry. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[46]  Ju Han Kim,et al.  Comprehensive analysis of differential gene expression profiles on D-galactosamine-induced acute mouse liver injury and regeneration. , 2006, Toxicology.

[47]  R. Knight,et al.  UniFrac: a New Phylogenetic Method for Comparing Microbial Communities , 2005, Applied and Environmental Microbiology.

[48]  N. Murphy,et al.  Management of acute liver failure , 2004 .

[49]  William M. Lee,et al.  Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States , 2002, Annals of Internal Medicine.

[50]  K. Böker,et al.  Akutes Leberversagen , 2001, Der Internist.